Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | VCP | P55072 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | TLR4 | O00206 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681205 | 1.00 | FBP1 (1.00) | FBP1APPEGFRVCPMAPT | |
| SCHEMBL6910815 | 0.89 | FBP1 (0.78) | FBP1EGFRVCPMAPTALDH1A1 | |
| SCHEMBL6910818 | 0.89 | FBP1 (0.78) | FBP1EGFRVCPMAPTALDH1A1 | |
| SCHEMBL9170804 | 0.86 | APP (0.78) | FBP1APPMAPTNPC1RAB9A | |
| SCHEMBL14947048 | 0.86 | APP (0.78) | FBP1APPMAPTNPC1RAB9A | |
| SCHEMBL458178 | 0.86 | APP (0.78) | FBP1APPMAPTNPC1RAB9A | |
| SCHEMBL458177 | 0.86 | APP (0.78) | FBP1APPMAPTNPC1RAB9A | |
| SCHEMBL9170800 | 0.86 | APP (0.78) | FBP1APPMAPTNPC1RAB9A | |
| SCHEMBL7622323 | 0.82 | APP (0.95) | FBP1APPMAPTNPC1RAB9A | |
| SCHEMBL11121103 | 0.82 | APP (0.95) | FBP1APPMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521208-B | Novel coronavirus 3CL protease inhibitor and application | 天津科技大学 | 2023-09-01 | — | — | CN | claimed |
| CN-115521208-A | Novel coronavirus 3CL protease inhibitor and application | 天津科技大学 | 2022-12-27 | — | — | CN | claimed |
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| CN-104277072-B | A kind of preparation method of (E)-2-aryl vinyl phosphate derivatives | JIANGSU CHINASUN SPECIALTY PRODUCTS CO.,LTD. (CN) | 2016-04-13 | — | — | CN | claimed |
| CN-104277072-A | Method for preparing (E)-2-aryl vinyl phosphonate derivatives | CHINASUN SPECIALTY PRODUCTS CO LTD | 2015-01-14 | — | — | CN | claimed |
| CN-101628904-B | Synthesis method of 2-nitro-3-aryl-2,3,5,7-tetrahydrobenzofuran-4-one derivative | UNIV SOOCHOW | 2012-04-25 | — | — | CN | claimed |
| CN-101343263-B | Method for synthesizing 5-nitro-4, 5-dihydrofuran derivative | UNIV SOOCHOW | 2012-04-04 | — | — | CN | claimed |
| CN-101628904-A | Synthesis method of 2-nitro-3-aryl-2,3,5,7-tetrahydrobenzofuran-4-one derivative | UNIV SOOCHOW | 2010-01-20 | — | — | CN | claimed |
| CN-101343263-A | Method for synthesis of 5-nitryl-4, 5-dihydrofuran derivant | UNIV SOOCHOW (CN) | 2009-01-14 | — | — | CN | claimed |
| CN-117983295-A | Chiral nanoparticle catalytic system for asymmetric Michael addition reaction and application thereof | 中国科学院大连化学物理研究所 | 2024-05-07 | — | — | CN | disclosed |
| CN-115521208-B | Novel coronavirus 3CL protease inhibitor and application | 天津科技大学 | 2023-09-01 | — | — | CN | disclosed |
| CN-116041241-A | Method for synthesizing pyrrole compound by solid acid catalysis | 浙江工业大学 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023012820-A1 | A PROCESS FOR THE PREPARATION OF GRAPIPRANT AND ITS INTERMEDIATES | ZENFOLD SUSTAINABLE TECHNOLOGIES PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | disclosed |
| CN-115521208-A | Novel coronavirus 3CL protease inhibitor and application | 天津科技大学 | 2022-12-27 | — | — | CN | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006015827-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
| US-4442264-A | UNSATURATED AROMATIC NITRO OR CHLORINE COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1984-04-10 | — | — | US | disclosed |
| US-3931220-A | FUNGICIDE, BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | FBP1 1093/4885APP 1442/4885EGFR 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.